Metformin intake is associated with better survival in ovarian cancer: A case-control study

Sanjeev Kumar, Alexandra Meuter, Prabin Thapa, Carrie Langstraat, Shailendra Giri, Jeremy Chien, Ramandeep Rattan, William Cliby, Viji Shridhar

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background: The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer. Methods: In this retrospective case-control study, women with ovarian cancer who received metformin (cases) were compared with women with ovarian cancer who did not receive metformin (controls). A 2-layered analysis was conducted. In preliminary analysis, all cases (the OC cohort) were compared with controls at a 1:2 ratio. Subsequently, in definitive analysis, only patients who had epithelial ovarian cancer (the EOC cohort) were compared with controls at a 1:3 ratio. In the EOC cohort, cases were matched with controls for age (±5 years), International Federation of Gynecology and Obstetrics stage, and residual disease. Prognostic variables and disease specific survival were compared using chi-square tests, the Kaplan-Meier (log-rank) method, and Cox proportional hazards analysis. Results: In a preliminary analysis of the OC cohort (72 cases and 143 controls), cases had better survival (5-year disease-specific survival for cases vs controls, 73% vs 44%; P =.0002). In the definitive analysis of the EOC cohort (61 cases and 178 controls), the distribution of age, disease stage, optimal cytoreduction, serous histology, and platinum chemotherapy remained similar between cases and controls (P >.05). Despite these similarities, cases had significantly better survival (5-year disease-specific survival for cases vs controls, 67% vs 47%; P =.007). On multivariate analysis, metformin remained an independent predictor of survival (hazard ratio, 2.2; 95% confidence interval, 1.2-3.8; P =.007) after controlling for disease stage, grade, histology, chemotherapy, body mass index, and surgical cytoreduction. Conclusions: The results of this study indicated an association of metformin intake with survival in patients with ovarian cancer. The receipt of metformin was associated with better survival, and the authors concluded that metformin is worthy of clinical trials in ovarian cancer. Cancer 2013.

Original languageEnglish (US)
Pages (from-to)555-562
Number of pages8
JournalCancer
Volume119
Issue number3
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Metformin
Ovarian Neoplasms
Case-Control Studies
Survival
Histology
Cohort Studies
Drug Therapy
Age Distribution
Chi-Square Distribution
Platinum
Gynecology
Obstetrics
Body Mass Index
Multivariate Analysis
Clinical Trials
Confidence Intervals

Keywords

  • drug repositioning
  • metformin
  • ovarian cancer
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kumar, S., Meuter, A., Thapa, P., Langstraat, C., Giri, S., Chien, J., ... Shridhar, V. (2013). Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer, 119(3), 555-562. https://doi.org/10.1002/cncr.27706

Metformin intake is associated with better survival in ovarian cancer : A case-control study. / Kumar, Sanjeev; Meuter, Alexandra; Thapa, Prabin; Langstraat, Carrie; Giri, Shailendra; Chien, Jeremy; Rattan, Ramandeep; Cliby, William; Shridhar, Viji.

In: Cancer, Vol. 119, No. 3, 01.02.2013, p. 555-562.

Research output: Contribution to journalArticle

Kumar, S, Meuter, A, Thapa, P, Langstraat, C, Giri, S, Chien, J, Rattan, R, Cliby, W & Shridhar, V 2013, 'Metformin intake is associated with better survival in ovarian cancer: A case-control study', Cancer, vol. 119, no. 3, pp. 555-562. https://doi.org/10.1002/cncr.27706
Kumar, Sanjeev ; Meuter, Alexandra ; Thapa, Prabin ; Langstraat, Carrie ; Giri, Shailendra ; Chien, Jeremy ; Rattan, Ramandeep ; Cliby, William ; Shridhar, Viji. / Metformin intake is associated with better survival in ovarian cancer : A case-control study. In: Cancer. 2013 ; Vol. 119, No. 3. pp. 555-562.
@article{567cf63ae41947adb14f2db5954a730b,
title = "Metformin intake is associated with better survival in ovarian cancer: A case-control study",
abstract = "Background: The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer. Methods: In this retrospective case-control study, women with ovarian cancer who received metformin (cases) were compared with women with ovarian cancer who did not receive metformin (controls). A 2-layered analysis was conducted. In preliminary analysis, all cases (the OC cohort) were compared with controls at a 1:2 ratio. Subsequently, in definitive analysis, only patients who had epithelial ovarian cancer (the EOC cohort) were compared with controls at a 1:3 ratio. In the EOC cohort, cases were matched with controls for age (±5 years), International Federation of Gynecology and Obstetrics stage, and residual disease. Prognostic variables and disease specific survival were compared using chi-square tests, the Kaplan-Meier (log-rank) method, and Cox proportional hazards analysis. Results: In a preliminary analysis of the OC cohort (72 cases and 143 controls), cases had better survival (5-year disease-specific survival for cases vs controls, 73{\%} vs 44{\%}; P =.0002). In the definitive analysis of the EOC cohort (61 cases and 178 controls), the distribution of age, disease stage, optimal cytoreduction, serous histology, and platinum chemotherapy remained similar between cases and controls (P >.05). Despite these similarities, cases had significantly better survival (5-year disease-specific survival for cases vs controls, 67{\%} vs 47{\%}; P =.007). On multivariate analysis, metformin remained an independent predictor of survival (hazard ratio, 2.2; 95{\%} confidence interval, 1.2-3.8; P =.007) after controlling for disease stage, grade, histology, chemotherapy, body mass index, and surgical cytoreduction. Conclusions: The results of this study indicated an association of metformin intake with survival in patients with ovarian cancer. The receipt of metformin was associated with better survival, and the authors concluded that metformin is worthy of clinical trials in ovarian cancer. Cancer 2013.",
keywords = "drug repositioning, metformin, ovarian cancer, survival",
author = "Sanjeev Kumar and Alexandra Meuter and Prabin Thapa and Carrie Langstraat and Shailendra Giri and Jeremy Chien and Ramandeep Rattan and William Cliby and Viji Shridhar",
year = "2013",
month = "2",
day = "1",
doi = "10.1002/cncr.27706",
language = "English (US)",
volume = "119",
pages = "555--562",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Metformin intake is associated with better survival in ovarian cancer

T2 - A case-control study

AU - Kumar, Sanjeev

AU - Meuter, Alexandra

AU - Thapa, Prabin

AU - Langstraat, Carrie

AU - Giri, Shailendra

AU - Chien, Jeremy

AU - Rattan, Ramandeep

AU - Cliby, William

AU - Shridhar, Viji

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Background: The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer. Methods: In this retrospective case-control study, women with ovarian cancer who received metformin (cases) were compared with women with ovarian cancer who did not receive metformin (controls). A 2-layered analysis was conducted. In preliminary analysis, all cases (the OC cohort) were compared with controls at a 1:2 ratio. Subsequently, in definitive analysis, only patients who had epithelial ovarian cancer (the EOC cohort) were compared with controls at a 1:3 ratio. In the EOC cohort, cases were matched with controls for age (±5 years), International Federation of Gynecology and Obstetrics stage, and residual disease. Prognostic variables and disease specific survival were compared using chi-square tests, the Kaplan-Meier (log-rank) method, and Cox proportional hazards analysis. Results: In a preliminary analysis of the OC cohort (72 cases and 143 controls), cases had better survival (5-year disease-specific survival for cases vs controls, 73% vs 44%; P =.0002). In the definitive analysis of the EOC cohort (61 cases and 178 controls), the distribution of age, disease stage, optimal cytoreduction, serous histology, and platinum chemotherapy remained similar between cases and controls (P >.05). Despite these similarities, cases had significantly better survival (5-year disease-specific survival for cases vs controls, 67% vs 47%; P =.007). On multivariate analysis, metformin remained an independent predictor of survival (hazard ratio, 2.2; 95% confidence interval, 1.2-3.8; P =.007) after controlling for disease stage, grade, histology, chemotherapy, body mass index, and surgical cytoreduction. Conclusions: The results of this study indicated an association of metformin intake with survival in patients with ovarian cancer. The receipt of metformin was associated with better survival, and the authors concluded that metformin is worthy of clinical trials in ovarian cancer. Cancer 2013.

AB - Background: The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer. Methods: In this retrospective case-control study, women with ovarian cancer who received metformin (cases) were compared with women with ovarian cancer who did not receive metformin (controls). A 2-layered analysis was conducted. In preliminary analysis, all cases (the OC cohort) were compared with controls at a 1:2 ratio. Subsequently, in definitive analysis, only patients who had epithelial ovarian cancer (the EOC cohort) were compared with controls at a 1:3 ratio. In the EOC cohort, cases were matched with controls for age (±5 years), International Federation of Gynecology and Obstetrics stage, and residual disease. Prognostic variables and disease specific survival were compared using chi-square tests, the Kaplan-Meier (log-rank) method, and Cox proportional hazards analysis. Results: In a preliminary analysis of the OC cohort (72 cases and 143 controls), cases had better survival (5-year disease-specific survival for cases vs controls, 73% vs 44%; P =.0002). In the definitive analysis of the EOC cohort (61 cases and 178 controls), the distribution of age, disease stage, optimal cytoreduction, serous histology, and platinum chemotherapy remained similar between cases and controls (P >.05). Despite these similarities, cases had significantly better survival (5-year disease-specific survival for cases vs controls, 67% vs 47%; P =.007). On multivariate analysis, metformin remained an independent predictor of survival (hazard ratio, 2.2; 95% confidence interval, 1.2-3.8; P =.007) after controlling for disease stage, grade, histology, chemotherapy, body mass index, and surgical cytoreduction. Conclusions: The results of this study indicated an association of metformin intake with survival in patients with ovarian cancer. The receipt of metformin was associated with better survival, and the authors concluded that metformin is worthy of clinical trials in ovarian cancer. Cancer 2013.

KW - drug repositioning

KW - metformin

KW - ovarian cancer

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84872978681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872978681&partnerID=8YFLogxK

U2 - 10.1002/cncr.27706

DO - 10.1002/cncr.27706

M3 - Article

C2 - 23208739

AN - SCOPUS:84872978681

VL - 119

SP - 555

EP - 562

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -